Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06814275 · ClinicalTrials.gov registry record · NA
Project neuroARTEMIS
A NA study of Depression and Human Immunodeficiency Virus (HIV), sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- NA
- Development phase
- 189
- Enrollment target
- 1
- Study location
NCT06814275: Recruiting NA study of Depression and Human Immunodeficiency Virus (HIV), sponsored by Wake Forest University Health Sciences.
NCT06814275 is a NA study of Depression and Human Immunodeficiency Virus (HIV) that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 189 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06814275, a NA study of Depression and Human Immunodeficiency Virus (HIV), is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 189 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to understand how chronic stress affects the way our brain and immune systems function, and in turn how this affects the way people feel, think, and behave. By learning more about how these processes work, the hope is to be able to develop better treatments to help with problems like depression and substance use. This study is intended for individuals that are HIV positive, currently taking prescription antiretroviral medications, and use stimulants. Through this intervention, the aim is to determine if this positive affect intervention can lead to reductions in stimulant use and depressed mood.
Primary Outcome
Functional connectivity (FC) will be derived from the the resting-state functional MRI data. Using a theory-driven, seed-based approach, the 4D time series \[average blood oxygenation level dependent (BOLD) signal across voxels\] will be extracted from a priori seeds in the reward network (i.e., nucleus accumbens, subgenual anterior cingulate cortex, medial orbitofrontal cortex). Normalized Z-scores will be calculated for FC between regions of interest. These analyses will control for baseline F
Conditions Studied
Interventions
- BEHAVIORAL ARTEMIS
- BEHAVIORAL Contingency management for Antiretroviral (ARV) adherence
Study Locations (1)
North Carolina
- Wake Forest University School of Medicine - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What NCT06814275 shows while recruiting
NCT06814275 is an interventional study that assigns participants to a tested intervention. The registered 189 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (76% lower).
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which ARTEMIS is the first listed.
NCT06814275 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06814275 about?
NCT06814275 is a clinical study titled "Project neuroARTEMIS". The purpose of this research is to understand how chronic stress affects the way our brain and immune systems function, and in turn how this affects the way people feel, think, and behave. By learning more about how these processes work, the hope is to be able to develop better treatments to help wi...
What is the current status of trial NCT06814275?
This trial is currently recruiting. It is a NA study. The enrollment target is 189 participants. The study started on 2025-04-29. Estimated completion is 2028-12-31.
What conditions does trial NCT06814275 study?
This clinical trial studies the following conditions: Depression, Human Immunodeficiency Virus (HIV), Stimulant Use.
What interventions are being tested in trial NCT06814275?
The interventions under investigation include: ARTEMIS (BEHAVIORAL), Contingency management for Antiretroviral (ARV) adherence (BEHAVIORAL).
Who is sponsoring clinical trial NCT06814275?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06814275 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06814275's enrollment target sits among peer trials
189 217th of 679 higher than 463 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02734537 · 189 participants · Phase 2
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- NCT05058651 · 189 participants · Phase 2
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
- NCT05673408 · 189 participants
NIBP Validation Study
- NCT05994209 · 189 participants · Phase 1
Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy